959237-68-4

Basic information

• Product Name: 2,4-DICHLORO-7-BROMOQUINAZOLINE
• Synonyms: 2,4-DICHLORO-7-BROMOQUINAZOLINE;7-Bromo-2,4-dichloroquinazoline
• CAS NO: 959237-68-4
• Molecular Formula: C₈H₃BrCl₂N₂
• Molecular Weight: 277.94
• Mol File: 959237-68-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 330.2±24.0 °C(Predicted)
• Appearance: /
• Density: 1.851±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.17±0.30(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-7-BROMOQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-7-BROMOQUINAZOLINE(959237-68-4)
• EPA Substance Registry System: 2,4-DICHLORO-7-BROMOQUINAZOLINE(959237-68-4)

Safety Data

• Hazardous Substances Data: 959237-68-4(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-7-bromoquinazoline is a chemical compound with the molecular formula C9H5Cl2N2Br. It is a heterocyclic compound that contains both chlorine and bromine atoms. 2,4-DICHLORO-7-BROMOQUINAZOLINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and diverse reactivity make it a valuable building block for the production of various organic compounds. However, it is important to handle this chemical with care, as it can be hazardous if not properly managed.

Upstream product

• 591-19-5 m-Bromoaniline 
• 114703-12-7 7-bromoquinazoline-2,4(1H,3H)-dione 
• 6326-79-0 6-bromoisatin 
• 65971-74-6 N-(3-bromophenyl)-2-(hydroxyimino)ethanamide 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 20776-48-1 2-amino-6-chlorobenzoic acid 

Downstream Products

• 1374203-78-7 4-(3-{2-fluoro-4-[7-(5-methyl-furan-2-yl)4-morpholin-4-yl-quinazolin-2-yl]-phenyl}ureido)dimethyl-benzamide 
• 1374203-80-1 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylic acid 
• 1374208-57-7 methyl 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylate 
• 1374203-82-3 4-(3-(4-(7-(5-cyanofuran-2-yl)-4-morpholino-quinazolin-2-yl)-3-fluorophenyl)ureido)-N,N-dimethyl-benzamide 
• 1374203-83-4 4-(3-(4-(7-(5-acetylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-2-fluoro-N,N-dimethyl-benzamide 
• 1374203-87-8 N-(4-(3-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)phenyl)acetamide 
• 1374203-88-9 1-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)-3-(4-(2-oxopyrrolidin-1-yl)phenyl)urea 
• 1374203-71-0 N,N-dimethyl-4-(3-{4-[4-morpholin-4-yl-7-pyrimidin-5-yl-quinazolin-2-yl]-phenyl}-ureido)-benzamide 
• 1374203-73-2 4-(3-{5-[7-(3-methanesulfonyl-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-pyridin-2-yl}-ureido)-dimethyl-benzamide 
• 1374208-37-3 4-(2-chloro-7-(3-(methylsulfonyl)phenyl)quinazolin-4-yl)morpholine 
• 1374208-38-4 5-[7-(3-methanesulfonyl-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-pyridin2-ylamine 
• 1334602-72-0 7-bromo-2,4-bis(4-methoxybenzyloxy)quinazoline 
• 1334602-73-1 2,4-bis(4-methoxybenzyloxy)-7-morpholin-4-ylquinazoline 

Relevant articles and documents

Synthesis, Inhibitory Activity, and in Silico Modeling of Selective COX-1 Inhibitors with a Quinazoline Core

Selective cyclooxygenase-1 (COX-1) inhibition has got into the spotlight with the discovery of COX-1 upregulation in various cancers and the cardioprotective role of COX-1 in control of thrombocyte aggregation. Yet, COX-1-selective inhibitors are poorly explored. Thus, three series of quinazoline derivatives were prepared and tested for their potential inhibitory activity toward COX-1 and COX-2. Of the prepared compounds, 11 exhibited interesting COX-1 selectivity, with 8 compounds being totally COX-1-selective. The IC50 value of the best quinazoline inhibitor was 64 nM. The structural features ensuring COX-1 selectivity were elucidated using in silico modeling.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS

The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorde